Blue Horseshoe Stocks: Stellar Options Calls & More

Valeant Pharmaceuticals, Inc. VRX – Options Recap

In yesterday morning’s premarket report, we noted that VRX had been coming off of recent annual lows, had a beat on earnings, and was up considerably in early trading.

Our exact words were “We want to formulate an options idea to coincide with the increased activity and expected price action in a stock in this position. We’ve seen this sort of pattern many times before, and if things play out similarly here, the VRX Weekly $10.50-12 Calls could be in line to see considerable gains.” Things did play out similarly. We did indeed see considerable gains, and quite frankly, that’s an understatement.

As VRX itself traded from 10.57 to 12.43, our targeted options calls posted astronomical moves on the day, giving traders a chance to grab a piece of the following gains:

$10.50 Calls – Range: .40-.1.92 – Max Gain: 380%
$11 Calls – Range: .18-1.50 – Max Gain: 733%
$11.50 Calls – Range: .08-1.05 – Max Gain: 1212%
$12 Calls – Range: .02-.74 – Max Gain: 3600%

This wasn’t even the first percentage gain in the thousands that we’ve rooted out in the past week. The SPY Weekly $238-50-239.50 Calls that we highlighted in Friday morning’s premarket report yielded a 4600% gainer on that day. Both of these plays serve as perfect examples of why we don’t limit our daily reports to stocks alone.

Cleantech Solutions International, Inc. CLNT

We did have a very nice play on the stock side of things as well yesterday, after we tagged CLNT in our extended watchlist. It ended up making a solid early push from a low of 4.11, and ran as high as 6.99 inside the first hour of trading.

That was good for intraday gains of up to 70% which we feel is quite good for a stock in this price range. CLNT is pulling back in premarket, but we will remain interested in possible bounce activity in the event that it holds support above yesterday’s swing low.

Proteon Therapeutics, Inc. PRTO

There’s an interesting situation unfolding with PRTO that warrants placing the stock on watch today. Despite reporting Q1 losses of $6.5M, the stock is gapping up heavily on the strength of a concurrent announcement. It pertains to the fact that the company’s investigatory treatment, vonapanitase, has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA).

Whenever such FDA news hits wires the resultant activity on the chart is sure to be interesting, which is evidenced by the the fact that traders are ignoring the disappointing quarterly figures that coincided with this event. Thus we are eager to track PRTO as we head through midweek.

Extended Watchlist: